Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.30 |
| ▸ | NOS1 | P29475 | 3/20 | 0.30 |
| ▸ | NOS2 | P35228 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL194675 | 1.00 | — | — | |
| SCHEMBL687177 | 1.00 | NOS3 (0.30) | NOS3NOS1NOS2 | |
| SCHEMBL3273283 | 1.00 | NOS3 (0.30) | NOS3NOS1NOS2 | |
| SCHEMBL1823136 | 1.00 | NOS3 (0.30) | NOS3NOS1NOS2 | |
| SCHEMBL495581 | 1.00 | — | — | |
| SCHEMBL4294 | 1.00 | — | — | |
| SCHEMBL206353 | 1.00 | NOS3 (0.30) | NOS3NOS1NOS2 | |
| SCHEMBL6575355 | 1.00 | NOS3 (0.30) | NOS3NOS1NOS2 | |
| SCHEMBL9808297 | 1.00 | NOS3 (0.30) | NOS3NOS1NOS2 | |
| SCHEMBL1432 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603929-B1 | SOLUBLE GROUP-10 ALPHA-DIIMINE CATALYST PRECURSORS | EXXONMOBIL CHEM PATENTS INC (US) | 2007-08-01 | — | — | EP | claimed |
| US-7160834-B2 | Soluble group-10 α-diimine catalyst precursors, catalysts and methods for dimerizing and oligomerizing olefins | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-01-09 | — | — | US | claimed |
| EP-1603929-A1 | SOLUBLE GROUP-10 ALPHA-DIIMINE CATALYST PRECURSORS | ExxonMobil Chemical Patents, Inc., A Corporation of the State of Delaware (US) | 2005-12-14 | — | — | EP | claimed |
| WO-2004083224-A1 | SOLUBLE GROUP-10 α-DIIMINE CATALYST PRECURSORS, | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2004-09-30 | — | — | WO | claimed |
| US-20040186010-A1 | Soluble group-10 alpha-diimine catalyst precursors, catalysts and methods for dimerizing and oligomerizing olefins | EXXONMOBIL CHEMICAL PATENTS INC. | 2004-09-23 | — | — | US | claimed |
| EP-0103465-B1 | 20-AMINO MACROLIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1986-09-10 | — | — | EP | claimed |
| EP-0058779-B1 | CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS MEDICINES | Dr. Karl Thomae GmbH (DE) | 1984-09-19 | — | — | EP | claimed |
| EP-0103465-A1 | 20-Amino macrolide derivatives | ELI LILLY AND COMPANY (US) | 1984-03-21 | — | — | EP | claimed |
| EP-0023569-A1 | Derivatives of carboxylic acids, their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1981-02-11 | — | — | EP | claimed |
| EP-2162435-B1 | Ionic liquids as electrolytes | INVISTA TECH SARL (CH) | 2013-09-04 | — | — | EP | disclosed |
| EP-1854792-B1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2012-12-26 | — | — | EP | disclosed |
| US-20120190844-A1 | IONIC LIQUIDS | INVISTA NORTH AMERICA S.A R.L. (US) | 2012-07-26 | — | — | US | disclosed |
| US-8088917-B2 | Ionic liquids | INVISTA NORTH AMERICA S.A R.L. (US) | 2012-01-03 | — | — | US | disclosed |
| US-7820693-B2 | 1-(2H)-isoquinolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-10-26 | — | — | US | disclosed |
| EP-0058779-B1 | CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS MEDICINES | Dr. Karl Thomae GmbH (DE) | 1984-09-19 | — | — | EP | disclosed |
| EP-0063826-A2 | 2-Amino-benzoic-acid derivatives, their preparation and their use as medicines or intermediates | Dr. Karl Thomae GmbH (DE) | 1982-11-03 | — | — | EP | disclosed |
| US-4353826-A | ANTITUBERCULAR ANTIBIOTICS | CIBA-GEIGY CORPORATION (US) | 1982-10-12 | — | — | US | disclosed |
| EP-0058779-A2 | Carboxamides, their preparation and their use as medicines | Dr. Karl Thomae GmbH (DE) | 1982-09-01 | — | — | EP | disclosed |
| US-4261891-A | BACTERICIDES, ANTITUBERCULAR AGENTS | CIBA-GEIGY CORPORATION (US) | 1981-04-14 | — | — | US | disclosed |
| EP-0023569-A1 | Derivatives of carboxylic acids, their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1981-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190844-A1 | IONIC LIQUIDS | INF2, H1-2, H1-0 | NOS3 451/4885NOS1 514/4885NOS2 154/4885 |
| US-20040186010-A1 | Soluble group-10 alpha-diimine catalyst precursors, catalysts and methods for dimerizing and oligomerizing olefins | OCIAD1, COG7, OCIAD2 | NOS3 528/4885NOS1 288/4885NOS2 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.